Dossier assessment
Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V
Report documents
-
Extract of dossier assessment
Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V
-
Dossier assessment
Mirikizumab (ulcerative colitis) - Benefit assessment according to § 35a Social Code Book V
Dossier assessment
Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment
- Patients who have had an inadequate response with, lost response to, or are intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response with, lost response to, or are intolerant to biologic treatment: added benefit not proven
Project details
- Project no.
- A23-73
- Commission
- Commission awarded on 14.07.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://dx.doi.org/10.60584/A23-73
Connected Projects
-
Dossier assessment
Mirikizumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed